Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB)

CUSIP: 034569103

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class
Equity / Common Stock
Shares outstanding
41,587,315
Total 13F shares
7,306,365
Share change
+27,372
Total reported value
$20,969,328
Price per share
$2.87
Number of holders
14
Value change
+$85,916
Number of buys
6
Number of sells
6

Quarterly Holders Quick Answers

What is CUSIP 034569103?
CUSIP 034569103 identifies ANEB - Anebulo Pharmaceuticals, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of ANEB - Anebulo Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
22NW, LP
13F
Company
13%
5,366,290
$12,986,422 31 Dec 2023
13F
LVW Advisors, LLC
13F
Company
1.5%
643,039
$1,556,155 31 Dec 2023
13F
Nantahala Capital Management, LLC
13F
Company
1.2%
511,073
$1,236,797 31 Dec 2023
13F
MORGAN STANLEY
13F
Company
0.96%
399,219
$966,110 31 Dec 2023
13F
Ikarian Capital, LLC
13F
Company
0.38%
157,862
$382,026 31 Dec 2023
13F
VANGUARD GROUP INC
13F
Company
0.37%
153,003
$370,267 31 Dec 2023
13F
BOOTHBAY FUND MANAGEMENT, LLC
13F
Company
0.05%
18,978
$45,927 31 Dec 2023
13F
LANDSCAPE CAPITAL MANAGEMENT, L.L.C.
13F
Company
0.04%
15,000
$36,300 31 Dec 2023
13F
Tower Research Capital LLC (TRC)
13F
Company
0.02%
9,102
$22,027 31 Dec 2023
13F
BlackRock Finance, Inc.
13F
Company
0.01%
4,145
$10,031 31 Dec 2023
13F
ADAR1 Capital Management, LLC
13F
Company
0%
1,217
$2,945 31 Dec 2023
13F
WELLS FARGO & COMPANY/MN
13F
Company
0%
61
$148 31 Dec 2023
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
4
$10 31 Dec 2023
13F
Simon Allen
3/4/5
Chief Executive Officer, Director
class O/S missing
70,246
09 Dec 2022
Karah Herdman Parschauer
3/4/5
Director
class O/S missing
30,425
21 Apr 2022

Institutional Holders of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) as of Q1 2024

As of 31 Mar 2024, Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) was held by 14 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 7,306,365 shares. The largest 10 holders included 22NW, LP, LVW Advisors, LLC, Nantahala Capital Management, LLC, MORGAN STANLEY, Ikarian Capital, LLC, VANGUARD GROUP INC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, GEODE CAPITAL MANAGEMENT, LLC, BOOTHBAY FUND MANAGEMENT, LLC, and Tower Research Capital LLC (TRC). This page lists 14 institutional shareholders reporting positions in this security for the Q1 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q1 2024 vs Q4 2023 Across Filers

Q4 2023 holders
13
Q1 2024 holders
14
Holder diff
1
Investor Q4 2023 Shares Q1 2024 Shares Share Diff Share Chg % Q4 2023 Value $ Q1 2024 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .